《嘉德诺Cardinal Health（CAH） 2024财年年度报告「NYSE」（英文版）（108页）.pdf》由会员分享，可在线阅读，更多相关《嘉德诺Cardinal Health（CAH） 2024财年年度报告「NYSE」（英文版）（108页）.pdf（108页珍藏版）》请在三个皮匠报告上搜索。

1、24AnnualreportCardinal Health Fiscal 2024 Annual Report434942_5PR24-3013324_FY24_Annual_Report_Cover_Wrap_Broch_PRINT_FINAL_v3_R2_CVR.indd 3434942_5PR24-3013324_FY24_Annual_Report_Cover_Wrap_Broch_PRINT_FINAL_v3_R2_CVR.indd 39/13/24 11:22 PM9/13/24 11:22 PMDear Shareholders,Today,we remain a strong,

2、focused and resilient company,and in fiscal 2024,we:Throughout fiscal 2024,our management team and Board of Directors continued to work through a comprehensive review of the companys strategy,portfolio,capital allocation framework and operations.These efforts have helped maximize our potential for t

3、he benefit of all stakeholders.In June 2023,we concluded our review of the former Pharmaceutical segment,highlighted at our 2023 Investor Day,with our enhanced organizational and growth focus on Specialty and our decision to retain and further invest in our Nuclear and Precision Health Solutions bus

4、iness.In January 2024,we updated our enterprise operating and segment reporting structure to both increase focus on our core and accelerate our growth areas.This new structure includes two reportable segments:Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution(GMPD).A

5、dditionally,Nuclear and Precision Health Solutions(NPHS),at-Home Solutions and OptiFreight Logistics are now included in Other1,an alignment designed to provide greater visibility into the performance of these three businesses.After our extensive review of the GMPD business,in August,we emphasized t

6、he continued execution of our GMPD Improvement Plan and announced new plans to unlock additional value for shareholders through further simplification and working capital improvements in the segment.The Business Review Committee of our Board sunsetted in July,as planned;the full Board will continue